El Vínculo El Vínculo.
Prior notice European Union Supplies

Markedshøring Oncotype DX

Buyer: Region Sjælland

Published
23 December 2024
Lots
1
Documents
1
Notice number
00790159-2024
Official source
Official source

CPV codes

Description

Region Zealand is assisting the Danish Health Technology Council in conducting a market consultation about the existence of any CE marked non-invasive prognostic test to guide adjuvant chemotherapy treatment decisions for individuals with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage (I-IIIa) invasive breast cancer. The test provides two pieces of information: 1. the recurrence risk and 2. the benefit of adding chemotherapy in order to reduce the risk. The test analyses the expression of 21 genes in breast tumour tissue based on RT-PCR. It does not require additional tumour material beyond the surgically excised tissue. This is the case because a company has requested the Danish Health Technology Council to assess their non-invasive prognostic test to guide adjuvant chemotherapy treatment decisions for individuals with HR+, HER2-, I-IIIa invasive breast cancer.

Official publications

Other tenders from Region Sjælland

Frequently asked questions

Who is the buyer of this tender?
The contracting authority is Region Sjælland (European Union).
How can I bid for public tenders in European Union?
Bids are submitted through the official procurement portal of European Union. El Vínculo helps you find tenders and analyse their documents; submission always happens at the official source.
Get alerts for tenders like this
Create a free account and receive new tenders from European Union matching your business, every day.

Start for free

Data collected from official public procurement sources. Amounts as published by the buyer.